¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º g]E>e v{`  
QeNN*@ ='i  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ }>< v7  
|.Vs(0O  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) IAzi:ct  
:XaBCF*  
1. ICAM-1  "DsL$D2e  
q>Kzl/~c.P  
2. interleukin 12(IL-12) mq6 TwM  
y,cz;2  
3. tumor infiltrating lymphocyte &^1{x`Qo=  
y';"tDFb  
4. TCR/CD3 complex \_8.\o"@*#  
EEdU\9DH(  
5. hematopoietin receptor family qEajT"?  
83g$k 9lG.  
6. individual idiotype(IdI) GW\66$|  
;<N%D=;}@  
7. integrin uN+]q qCf  
/ lDei}  
8. colony-stimulatory factor (CSF) C q)Cwc[H  
J1g+H2  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© r2G38/K  
#b wGDF  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? SI, t:=D  
(C.<H6]=  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ H7dT6`<~Y  
p-XO4Pc 6  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ4~ i?xo=;v  
w9TE E,t;5  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ 8e32NJ^k~  
3 nnoXc'  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) $Ts;o  
3@42u G>  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ TyY%<NCIb  
53WCF[  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) qs!A)H#  
n zU;Bi^m  
3. immunoglobulin superfamily (IgSF) ksf6O$  
72ZoN<c  
4. selectin fcO|0cQ  
 :!Nx'F9a  
5. anti-idiotypic antibody (¦ÁId) Zc'^iDAY  
25 cJA4  
6. major histocompatibility complex(MHC) X;n09 L`CB  
3 Ak'Ue  
7. immunotolerance fN/;BT  
`<{LW>Lb  
8. biological reponse modifier(BRM) %o 5'M^U  
e_"m\e#N  
9. immune reponse gene (Ir gene) ZZL@UO>:  
N<ux4tz  
10. reshaped antibody (or reconstituted antibody) \KzH5?  
:%Oz:YxC/  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© d14n>  
.cHkh^EDY  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ k~gOL#$  
MB7*AA;  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? TEh.?  
_m[DieR  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ DIw_"$'At  
*c [^/  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? 0#DEh|?  
d$ n31F  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ /aMOZ=,q}  
A=5Ebu!z  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? vsZ?cd  
#CaPj:>[  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ ~!5=o{wy  
!{ (Bc8 hT  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ XC)9aC@s  
Hj|&P/jY]*  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? |Ia9bg'1U  
&v0-$  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ z&tC5]#  
Lr D@QBT  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: HyU:BW;  
kuy?n-1g  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: NBY|U{.g  
!T][c~l  
ÃâÒßѧ fk5'v   
 r!?ga  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© G/<zd)  
p35=CX`T.  
1. CD8 eZa*WI=  
,G t!nm_  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) *9EwZwE_K  
nc k/Dw  
3. immunoglobulin fold(Ig fold) pT]hPuC  
Xb%q9Z  
4. cadherin (Ca-dependent cell adhesion moleculers) vn^O m-\  
+?{"Q#.>;  
5. idiotype-anti-idiotypic antibody immune network theory _-_iw&F  
@.eN+o9|  
6. HLA class II antigen .*-8rOcc  
F?Lt-a+  
7. complementarity-determining region (CDR) Vke<; k-  
XjGS.&'I  
8. perforin(or pore-forming protein ,PFP) !cyrt<  
r N$0qo  
9. high affinity IL-2 receptor w \b+OW  
,eyh%k*hz  
10. artificial active immunization eP-|3$  
|(>`qL{|  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© }(nT(9|  
E!9WZY  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ}4|EHhG  
MGR:IOTa  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 cRT'?w`}  
>w S'z]T9  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ @_+aX. ,  
Nz dN4+  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ YYe G9yR  
+RooU?Aq  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ z?o8h N\  
E8PDIjp  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? _?~%+Oz/  
PgkU~68`  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 5XK Tb  
=-U0r$sK+F  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ enQ*uMKd^  
6 s=VU\  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ _;HdX$op  
(0 T!- hsP  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ TLwxP"  
X*2W4udF  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 'z$N{p40m  
rW?Wd Eg  
1. immunoglobulin gene rearrangement yv,FzF}7  
)?rq 8VO  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) h:4(Gm;  
s#X/ F  
3. flow cytometry(FCM) <i~xJi%1#  
+x%u?ZR  
4. carrier effect -@>{q/  
!^arWH[od  
5. positive selection of T lymphocytes in thymus ob7'''i  
o#qdgZ  
6. mouse TH1(Th1) and TH2(Th2) subsets Olzw)WjG  
7By7F:[b  
7. perforin (pore-forming protein ,PFP) ^6W}ZLp  
7@c!4hmrU  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) Nc+0_|,  
wv\X  
9. SH-2(src-homology region 2) :2/L1A)O  
k3Yu"GY^  
10. Ab2¦Â (internal image) k{vj,#  
>2#<gp3  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© kK5&?)3Y:  
Cd'D ~'=  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? ILuQ.VhBVN  
+yL;?+s>=  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? S?v/diK ]J  
ZA=J`- >k  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠX;LYGJ{Xk  
MZ3 8=nJ  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ aR2N,<Cp5  
!gI0"p?  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠD5"5`w=C  
5 3pW:`  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) Zv yZ5UA  
Lv+{@)  
ÃâÒßѧרҵ£º V_3oAu54s{  
6vNW)1{nn  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ ") 8l'^Mq2  
q%,86A>  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? NFVu~t  
-O &>HA  
´«È¾²¡Ñ§×¨Òµ£º pCkMm)2g!  
U_ VP\ 03  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ Nd(3q]{  
.7.1JT#@A7  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ KY&Lv^1_|  
7bYwh8  
Ïû»¯×¨Òµ£º 2:Yvr_L  
aUL7 ]'q}  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ E$lbm>jsb$  
XrUI [ryE  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? Zf>:h   
#;99vw c  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ O+&;,R:  
`Fcr`[  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© `BZ|[ q3  
pku\)  
1. Fas(CD95)/FasL =WUNBav  
BoT#b^l  
2. common chain of cytokine receptor !{,2uQXe  
NcbW"Qv3  
3 . TCR/CD3 complex 8nZ_.  
T0A=vh;S  
4. negaive selection of thymocytes 0]f/5 jvLj  
w nBvJb]4l  
5. artificial active immune N5W!(h)  
Wlg1t~1=  
6. anti-idiotypic v~ x`a0  
{|$kI`h,3-  
7. IgSF A1;'S<a  
x _kT Wq  
8. Integrin 9e.v[K~  
t"9r`0>  
9. chemokine {oAD;m`  
tSni[,4Kq  
10. B7/CD28 )" Z|x  
"*HEXru#B  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© ;9#%E  
'I}wN5`  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ >bI\pJ  
t(vyi  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ +t-_FbFh3D  
>`[+24e  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ =oq=``%  
K[?@nl?,z  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ 2^=.f?_YR  
eC<?g  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ YADXXQ"  
xY.?OHgG/  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ f`rI]v|@  
6~>h;wC  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© uT=5 zu  
ugj I$u  
1. B7/CD28 )p#L"r^)  
e\-,e+  
2. Th1 subset 1fM`n5?"  
y,OG9iD:h  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© |#BN!kc  
l+wfP76w  
4. antibody affinity maturation 6Z=Qs=q  
]Nssn\X7  
5. AP-1 QX&Y6CC`]  
xzFQ)t&  
6. single chain variable fragment£¨ScFv£© PRB lf  
r XBC M  
7. NK cell receptor 6kAGOjO  
}7xcHVO8-  
8. Zinkernagel-Doherty phenomenon &v;o }Q}E{  
$Xu/P5  
9. Ig fold bI(8Um6m  
s +qodb+  
10. CD40/CD40L paMK]-  
2}* 8( 32  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© f+1'Ah0'E  
Z.x]6  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ u]`0QxvZ  
C(8!("tU  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ u i$4  
rQ2TPX<?a  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ L`w r~E2u  
t. (6tL]  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ B[#n,ay  
"3a}~J<g  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ -okq= 9  
bC) <K/Q9  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ }s6Veosl  
e"{"g[b/7  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ SkCux  
!;d>}iE   
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© 8Z "f"  
_%\%  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© WB<MU:.Vc  
W!Hn`T   
1.Co-stimulators (or co-stimulating molecules) @t*D<B$  
$ e,r>tgD  
2.NK-kB NpKyrXDJv  
JL{fW>5y|  
3.Immunoglobulin superfamily esQ`6i  
.c@Y ?..+  
4.antigen-presenting cell (APC) kg7 bZ  
F+ RE  
5.death domain X=lsuKREZ  
0S'@(p[A  
6.CCR and CXCR ue@W@pj  
:xbj& l  
7.Lectin (or mitogen) ;volBfv  
:=5X)10  
8.Clusters of differentiation, CD) EA9 .?F  
\7#w@3*  
9.B7 family ?$uF(>LD  
3;wiwN'  
10.Cytotoxic T lymphocyte, CTL) [u^ fy<jdp  
!>=lah$&  
11.IL-15 and IL-15 receptor (IL-15R) q8;MPXSG3  
C+jXH)|iq  
12.MHC restriction %6Vb1?x  
c#1kg@q@  
13.Affinity-chromatography ) j&khHD  
*tk=DsRW  
14.Cyctosprin A, CsA a~Ld cUYs  
@p}_"BHYWt  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) a#[gNT~[  
!<VP[%2L~  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© Ea'jAIFPpO  
05\0g9  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 ` "-P g5  
n9k  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ &)JoB  
S')DAx  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ + @|u 8+  
r!eW]M  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 1>Vq<z  
T /IX(b'<  
ÃâÒßѧרҵ£º ; lrO?sm  
br 3-.g  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ &m[}%e%~0  
Mqk|H~l5c  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ %6^nb'l'C  
x?u@ j7[  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ 9^N(s7s  
) R5j?6}xF  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) *=v%($~PK6  
MZcvr9y  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) i ps)-1  
V EsM  
1. ADCC(antibody dependent cell-mediated cytotoxicity) 3XQe? 2:<  
1q5S"=+W[  
2. »·æß¾úËØ(cyclosporin) ht>/7.p]  
)b=vBs`%  
3. KIR(killer cell inhibitory receptor) nR@mm j  
8\:>;XG6f  
4. HLDA(human leucocyte differentiation antigen) _y>d rvg  
!TY0;is  
5. Interleukin 18(IL-18) 0pW;H|h  
1|ddG010  
6. ÕûºÏËØ(integrin) (4yXr|to}  
+t&)Z  
7. Fas/FasL vkR ~nIp  
'Z9UqEGV  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) kRbJK  
@icw:68  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) I5g|)Y Q  
Knb(MI6  
10. Th1/Th2 1uG)U)y/Q  
`U\l: ~]e  
11. »ùÒòÒßÃç(DNAÒßÃç)  Z,O-P9jC  
dBovcc  
12. chemokines and chemokine receptor L ed{#+  
AS~!YR  
13. ÃâÒßÄÍÊÜ : )B1|1  
s?->2gxhx  
14. ¹²´Ì¼¤·Ö×Ó 8@S]P0lk  
ZPq.|6&  
15. ËÀÍö½á¹¹Óò(death domain) ;/?w-)n?  
!T ,=kh  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) ev+H{5W8  
VnB HQ.C  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? e 6>j gy  
R~[~(`/S  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ}opMf6`w  
k&f/f  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î ,mi 7WW9  
83'+q((<  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ (0`w.n  
jJt4{c  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå L,nb<  
8d Fqwpw8  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ !dh:jPpKq  
r#& JfAo  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 1ZYo-a;)  
p>3QW3<  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ M3F1O6=4j  
} snS~kx  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ ~!g2+^G7+P  
UHU ,zgM  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»